CD4 TIL (TUMOR-INFILTRATING LYMPHOCYTES) INDUCE COMPLETE RESPONSE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA PREVIOUSLY TREATED WITH IL-2 - A PRELIMINARY-STUDY

This study analyzed clinical response induced by TIL in patients with renal cell carcinoma previously treated by interleukin-2. Six patients (4 men, 2 women, mean age 44,3 years) with measurable metastatic loca lizations have been treated by TIL reinjection (0,02 to 7,6 x 10(10) c ells). TIL phenotype was a combination of CD4 and CD8 in 3 patients, p redominantly CD4 in two patients and predominantly CD8 in one patient. Previous treatment by interleukin-2 induced one partial response, 2 s tabilizations of the disease and 3 tumoral progressions. TIL led to an amelioration for 4 patients: 2 were in complete response, 2 were stab ilized and 2 had tumoral progression and deceased. This study shows th at CD4 TIL may improve an initially response induced by IL-2 therapy.